TRISTEL PLC

Report Publication Announcement • Dec 12, 2022

National Storage Mechanism | Additional information

RNS Number : 4014J

Tristel PLC

12 December 2022

Tristel plc

("Tristel" or the "Company")

AGM Statement and notice of results

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at Lynx Business Park, Fordham Road, Newmarket, Cambridgeshire CB8 7NY.

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

"The Company is returning to its pre-pandemic growth trajectory, with first half revenue expected to exceed £17m, compared to £15m in the first half of last year. Revenue growth is consistent across all our geographical markets. Gross margin is in line with expectations.

"With respect to North America, we have made our first sales in the United States and Canada, and we are preparing the additional data requested by the FDA in September. We expect to submit it in March next year, meeting the FDA's deadline and facilitating a decision from the agency around our year-end in June.  We remain confident of a successful outcome.

"The Company is making good progress. With no debt and cash of approximately £10m we face the prevailing economic environment with confidence."

Notice of Results

The Company's unaudited interim results will be announced on 20 February 2023.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:     

## Tristel plc	Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Chief Financial Officer
Walbrook PR Ltd	Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Applegarth	Mob: 07584 391 303
finnCap	Tel: 020 7220 0500
Geoff Nash/ Charles Beeson (Corporate Finance)
Alice Lane (ECM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFFLFSLFLIF